DOCSLIB.ORG

Prospec (Product

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prospec (Product Name Catalog # Description Customer Price-A Customer Price-B Customer Price-C CYTOKINES AND GROWTH FACTORS Activin A, Active cyt-145 Recombinant Human Activin-A, Active $50/2µg $130/10µg $3,500/1mg Activin A, Plant-Active cyt-414 Recombinant Human Activin-A Active $50/1µg $130/5µg $1,500/100µg Activin A cyt-569 Recombinant Human Activin-A $50/2µg $130/10µg $2,700/1mg Activin A, Plant cyt-052 Recombinant Human Activin-A, Plant $50/2µg $130/10µg $4,800/1mg mActivin A cyt-146 Recombinant Mouse Activin-A $50/2µg $130/10µg $3,500/1mg rActivin A cyt-147 Recombinant Rat Activin-A $50/2µg $130/10µg $3,500/1mg Activin B, Active cyt-057 Recombinant Human Activin-B Active $50/2µg $130/10µg $5,200/1mg Activin B cyt-058 Recombinant Human Activin-B $50/2µg $130/10µg $4,800/1mg ACVR1 cyt-1140 Recombinant Human Activin A Receptor Type 1 $50/2µg $130/10µg $1,000/0.1mg ACVRL1 cyt-920 Recombinant Human Activin A Receptor Type II-Like 1 $50/2µg $130/10µg $5,200/1mg ACVR2A cyt-976 Recombinant Human Activin A Receptor Type 2A $50/2µg $130/10µg $5,200/1mg Acrp30 cyt-024 Human Adiponectin $50/2µg $130/10µg $1,000/0.1mg Acrp30 cyt-280 Recombinant Human Adiponectin $50/5µg $130/25µg $2,700/1mg Acrp30, His cyt-433 Recombinant Human Adiponectin, His tag $50/10µg $130/50µg $1,900/1mg Acrp30 (108-244) cyt-073 Recombinant Human Adiponectin (108-244 a.a.) $50/5µg $130/25µg $2,700/1mg Acrp30, HEK cyt-434 Recombinant Human Adiponectin glycosilated, HEK $50/2µg $130/10µg $4,680/1mg Acrp30, HMW cyt-764 Recombinant Human Adiponectin glycosilated, HMW Rich $50/2µg $130/10µg $4,680/1mg Acrp30, Tri cyt-233 Recombinant Human Adiponectin Trimeric Form $50/2µg $130/10µg $5,200/1mg Acrp30, Sf9 cyt-1002 Recombinant Human Adiponectin, Sf9 $50/1µg $130/5µg $1,200/50µg mAcrp30, HEK cyt-435 Recombinant Mouse Adiponectin glycosilated, HEK $50/2µg $130/10µg $4,680/1mg mAcrp30, His cyt-537 Recombinant Mouse Adiponectin, His tag $50/5µg $130/25µg $3,300/1mg mAcrp30, Tri cyt-247 Recombinant Mouse Adiponectin Trimeric Form $50/2µg $130/10µg $5,200/1mg pAcrp30, HEK cyt-696 Recombinant Porcine Adiponectin glycosilated, HEK $50/2µg $130/10µg $4,680/1mg rACRP30 cyt-831 Recombinant Rat Adiponectin $50/2µg $130/10µg $5,200/1mg gAcrp30 cyt-615 Recombinant Human Adiponectin Globular $50/5µg $130/25µg $2,700/1mg gAcrp30, His cyt-277 Recombinant Human Adiponectin Globular, His tag $50/2µg $130/10µg $2,800/1mg mgAcrp30 cyt-432 Recombinant Mouse Adiponectin Globular $50/10µg $130/50µg $1,800/1mg AIF1 cyt-697 Recombinant Human Allograft Inflammatory Factor 1 $50/2µg $130/10µg $4,680/1mg AIF1L cyt-007 Recombinant Human Allograft Inflammatory Factor 1 Like $50/5µg $130/20µg $2,700/1mg AITR cyt-925 Recombinant Human AITR $50/2µg $130/10µg $5,200/1mg AITRL cyt-076 Recombinant Human AITRL $50/5µg $130/20µg $2,700/1mg AITRL, His cyt-317 Recombinant Human AITRL, His Tag $50/5µg $130/20µg $2,700/1mg AITRL, T7 cyt-807 Recombinant Human AITRL, T7 Tag $50/2µg $130/10µg $5,200/1mg ANGPT1 cyt-074 Recombinant Human Angiopoietin-1 $50/5µg $130/20µg $2,700/1mg Name Catalog # Description Customer Price-A Customer Price-B Customer Price-C CYTOKINES AND GROWTH FACTORS ANGPT2 cyt-1103 Recombinant Human Angiopoietin-2 $50/2µg $130/10µg $1,200/100µg ANGPTL2 cyt-765 Recombinant Human Angiopoietin-like Protein 2 $50/2µg $130/10µg $5,200/1mg ANGPTL3 cyt-248 Recombinant Human Angiopoietin-like Protein 3 $50/2µg $130/10µg $4,800/1mg ANGPTL3, HEK cyt-766 Recombinant Human Angiopoietin-like Protein 3, HEK $50/2µg $130/10µg $1,200/100µg ANGPTL3 (243-460) cyt-902 Recombinant Human Angiopoietin-like Protein 3, (243-460 a.a.) $50/5µg $130/20µg $2,700/1mg ANGPTL3 (17-460) cyt-986 Recombinant Human Angiopoietin-like Protein 3, (17-460 a.a.) $50/2µg $130/10µg $5,200/1mg ANGPTL4 cyt-249 Recombinant Human Angiopoietin-like Protein 4 $50/2µg $130/10µg $4,800/1mg ANGPTL4, HEK cyt-698 Recombinant Human Angiopoietin-like Protein 4, HEK $50/2µg $130/10µg $4,800/1mg ANGPTL6 cyt-832 Recombinant Human Angiopoietin-like Protein 6 $50/2µg $130/10µg $5,200/1mg mANGPTL7 cyt-914 Recombinant Mouse Angiopoietin-like Protein 7 $50/1µg $130/5µg $500/25µg APOA1 cyt-750 Recombinant Human Apolipoprotein A-I $50/20µg $130/100µg $990/1mg APOA1, His cyt-661 Recombinant Human Apolipoprotein A-I, His Tag $50/20µg $130/100µg $1,000/1mg APOA1 cyt-037 Human Apolipoprotein A-I $50/20µg $130/100µg $600/1mg mAPOA1 cyt-891 Recombinant Mouse Apolipoprotein A-I $50/5µg $130/20µg $2,700/1mg APOA5, HEK cyt-025 Recombinant Human Apolipoprotein A-V, HEK $50/2µg $130/10µg $5,200/1mg APOA5 cyt-767 Recombinant Human Apolipoprotein A-V $50/2µg $130/10µg $5,200/1mg APOB cyt-1042 Human Apolipoprotein-B $150/100µg $990/1mg $4,000/5mg APOC1 cyt-812 Recombinant Human Apolipoprotein C-I $50/2µg $130/10µg $5,200/1mg APOD cyt-547 Recombinant Human Apolipoprotein-D $50/2µg $130/10µg $5,200/1mg APOD, HEK cyt-768 Recombinant Human Apolipoprotein-D, HEK $50/2µg $130/10µg $5,200/1mg APOD, GST cyt-652 Recombinant Human APO-D GST Tag $175/2µg $270/5µg $490/10µg APOE3 cyt-874 Recombinant Human Apolipoprotein E3 $50/100µg $200/500µg $350/1mg APOE4 cyt-968 Recombinant Human Apolipoprotein E4 $50/100µg $170/500µg $315/1mg APOH cyt-189 Recombinant Human Apolipoprotein-H $50/2µg $130/10µg $5,200/1mg Clusterin cyt-278 Recombinant Human Apolipoprotein-J $50/2µg $130/10µg $5,200/1mg Clusterin cyt-548 Human Apolipoprotein-J $50/2µg $130/10µg $4,800/1mg Clusterin, Serum cyt-1131 Human Apolipoprotein-J, Serum $50/2µg $130/10µg $4,800/1mg Clusterin, His cyt-814 Recombinant Human Apolipoprotein-J, His Tag $50/5µg $130/20µg $3,600/1mg rClusterin cyt-437 Recombinant Rat Apolipoprotein-J $50/2µg $130/10µg $3,600/1mg k9Clusterin cyt-549 Recombinant Canine Apolipoprotein-J $50/2µg $130/10µg $5,200/1mg k9Clusterin, HEK cyt-618 Recombinant Canine Apolipoprotein-J, HEK $50/2µg $130/10µg $5,200/1mg APOL4 cyt-785 Recombinant Human Apolipoprotein L 4 $50/2µg $130/10µg $1,200/100µg APOM cyt-715 Recombinant Human Apolipoprotein-M $50/2µg $130/10µg $5,200/1mg APOM, HEK cyt-026 Recombinant Human Apolipoprotein-M, HEK $50/2µg $130/10µg $5,200/1mg Name Catalog # Description Customer Price-A Customer Price-B Customer Price-C CYTOKINES AND GROWTH FACTORS APRIL cyt-815 Recombinant Human APRIL $50/5µg $130/20µg $2,700/1mg mAPRIL cyt-803 Recombinant Mouse APRIL $50/5µg $130/20µg $2,700/1mg AREG cyt-041 Recombinant Human Amphiregulin $50/10µg $130/50µg $1,350/1mg Artemin cyt-306 Recombinant Human Artemin $50/5µg $130/20µg $2,700/1mg BD1 cyt-564 Recombinant Human Beta Defensin-1 $50/5µg $130/20µg $2,700/1mg mBD1 cyt-044 Recombinant Mouse Beta Defensin-1 $50/5µg $130/20µg $2,700/1mg rBD1 cyt-062 Recombinant Rat Beta Defensin-1 $50/5µg $130/20µg $2,700/1mg BD2 cyt-571 Recombinant Human Beta Defensin-2 $50/5µg $130/20µg $2,700/1mg mBD2 cyt-035 Recombinant Mouse Beta Defensin-2 $50/5µg $130/20µg $2,700/1mg BD3 cyt-461 Recombinant Human Beta Defensin-3 $50/5µg $130/20µg $1,400/1mg mBD3 cyt-036 Recombinant Mouse Beta Defensin-3 $50/5µg $130/20µg $2,700/1mg rBD3 cyt-063 Recombinant Rat Beta Defensin-3 $50/5µg $130/20µg $2,700/1mg BD4 cyt-599 Recombinant Human Beta Defensin-4 $50/5µg $130/20µg $2,700/1mg rBD4 cyt-066 Recombinant Rat Beta Defensin-4 $50/5µg $130/20µg $2,700/1mg BD5 cyt-804 Recombinant Human Beta Defensin-5 $50/5µg $130/20µg $2,700/1mg mBD14 cyt-945 Recombinant Mouse Beta Defensin-14 $50/5µg $130/20µg $2,700/1mg BDNF cyt-207 Recombinant Human Brain-Derived Neurotrophic Factor $50/2µg $130/10µg $4,680/1mg BDNF, His cyt-881 Recombinant Human Brain-Derived Neurotrophic Factor, His Tag $50/5µg $130/20µg $2,700/1mg BDNF, HEK cyt-1081 Recombinant Human Brain-Derived Neurotrophic Factor, HEK $50/2µg $130/10µg $5,200/1mg proBDNF cyt-014 Recombinant Human Precursor Brain-Derived Neurotrophic Factor $50/2µg $130/10µg $5,200/1mg BAFF cyt-307 Recombinant Human BAFF (BLyS) $50/5µg $130/20µg $4,680/1mg BAFF, His cyt-545 Recombinant Human BAFF (BLyS), His Tag $50/5µg $130/20µg $3,600/1mg BAFF, Plant cyt-054 Recombinant Human BAFF (BLyS), Plant $50/1µg $130/5µg $1,500/100µg BAFFR cyt-429 Recombinant Human BAFF (BLyS) Receptor $50/10µg $130/50µg $1,350/1mg BMPR1A cyt-380 Recombinant Human Bone Morphogenetic protein Receptor-1A $50/2µg $130/10µg $4,000/1mg BMPR1A, IgG-His cyt-1005 Recombinant Human Bone Morphogenetic protein Receptor-1A, IgG-His $50/2µg $130/10µg $5,200/1mg BMPR1A, CHO cyt-1094 Recombinant Human Bone Morphogenetic protein Receptor-1A, CHO $600/50µg $900/100µg $4,200/1mg BMPR1B cyt-897 Recombinant Human Bone Morphogenetic protein Receptor-1B $50/2µg $130/10µg $1,200/100µg BMP2 cyt-261 Recombinant Human Bone Morphogenetic protein-2 $50/2µg $130/10µg $3,500/1mg BMP2, HEK cyt-080 Recombinant Human Bone Morphogenetic protein-2, HEK $50/2µg $130/10µg $1,200/100µg BMP2, Mono cyt-627 Recombinant Human Bone Morphogenetic protein-2 Monomer $50/5µg $130/20µg $2,100/1mg BMP3 cyt-937 Recombinant Human Bone Morphogenetic protein-3 $50/10µg $130/50µg $1,350/1mg BMP4 cyt-361 Recombinant Human Bone Morphogenetic protein-4 $50/2µg $130/10µg $2,900/1mg BMP4, HEK cyt-081 Recombinant Human Bone Morphogenetic protein-4 Active $50/2µg $130/10µg $1,100/100µg Name Catalog # Description Customer Price-A Customer Price-B Customer Price-C CYTOKINES AND GROWTH FACTORS BMP4, CHO cyt-1093 Recombinant Human Bone Morphogenetic protein-4 Active, CHO $50/2µg $130/10µg $1,000/100µg BMP5 cyt-660 Recombinant Human Bone Morphogenetic protein-5 $50/5µg $130/20µg $3,000/1mg BMP6 cyt-754 Recombinant Human Bone Morphogenetic protein-6 $50/2µg $130/10µg $950/100µg BMP7 cyt-333 Recombinant Human Bone Morphogenetic protein-7 $50/2µg $130/10µg $3,600/1mg
Load more

Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods
    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
    [Show full text]
  • Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin
    0163-769X/04/$20.00/0 Endocrine Reviews 25(3):426–457 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/er.2002-0029 Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin AART J. VAN DER LELY, MATTHIAS TSCHO¨ P, MARK L. HEIMAN, AND EZIO GHIGO Division of Endocrinology and Metabolism (A.J.v.d.L.), Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands; Department of Psychiatry (M.T.), University of Cincinnati, Cincinnati, Ohio 45237; Endocrine Research Department (M.L.H.), Eli Lilly and Co., Indianapolis, Indiana 46285; and Division of Endocrinology (E.G.), Department of Internal Medicine, University of Turin, Turin, Italy 10095 Ghrelin is a peptide predominantly produced by the stomach. secretion, and influence on pancreatic exocrine and endo- Ghrelin displays strong GH-releasing activity. This activity is crine function as well as on glucose metabolism. Cardiovas- mediated by the activation of the so-called GH secretagogue cular actions and modulation of proliferation of neoplastic receptor type 1a. This receptor had been shown to be specific cells, as well as of the immune system, are other actions of for a family of synthetic, peptidyl and nonpeptidyl GH secre- ghrelin. Therefore, we consider ghrelin a gastrointestinal tagogues. Apart from a potent GH-releasing action, ghrelin peptide contributing to the regulation of diverse functions of has other activities including stimulation of lactotroph and the gut-brain axis. So, there is indeed a possibility that ghrelin corticotroph function, influence on the pituitary gonadal axis, analogs, acting as either agonists or antagonists, might have stimulation of appetite, control of energy balance, influence clinical impact.
    [Show full text]
  • Organ Level Protein Networks As a Reference for the Host Effects of the Microbiome
    Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press 1 Organ level protein networks as a reference for the host effects of the microbiome 2 3 Robert H. Millsa,b,c,d, Jacob M. Wozniaka,b, Alison Vrbanacc, Anaamika Campeaua,b, Benoit 4 Chassainge,f,g,h, Andrew Gewirtze, Rob Knightc,d, and David J. Gonzaleza,b,d,# 5 6 a Department of Pharmacology, University of California, San Diego, California, USA 7 b Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 8 California, USA 9 c Department of Pediatrics, and Department of Computer Science and Engineering, University of 10 California, San Diego California, USA 11 d Center for Microbiome Innovation, University of California, San Diego, California, USA 12 e Center for Inflammation, Immunity and Infection, Institute for Biomedical Sciences, Georgia State 13 University, Atlanta, GA, USA 14 f Neuroscience Institute, Georgia State University, Atlanta, GA, USA 15 g INSERM, U1016, Paris, France. 16 h Université de Paris, Paris, France. 17 18 Key words: Microbiota, Tandem Mass Tags, Organ Proteomics, Gnotobiotic Mice, Germ-free Mice, 19 Protein Networks, Proteomics 20 21 # Address Correspondence to: 22 David J. Gonzalez, PhD 23 Department of Pharmacology and Pharmacy 24 University of California, San Diego 25 La Jolla, CA 92093 26 E-mail: [email protected] 27 Phone: 858-822-1218 28 1 Downloaded from genome.cshlp.org on October 6, 2021 - Published by Cold Spring Harbor Laboratory Press 29 Abstract 30 Connections between the microbiome and health are rapidly emerging in a wide range of 31 diseases.
    [Show full text]
  • Katalog 2015 Cover Paul Lin *Hinweis Förderung.Indd
    Product List 2015 WE LIVE SERVICE Certificates quartett owns two productions sites that are certified according to EN ISO 9001:2008 Quality management systems - Requirements EN ISO 13485:2012 + AC:2012 Medical devices - Quality management systems - Requirements for regulatory purposes GMP Conformity Our quality management guarantees products of highest quality! 2 Foreword to the quartett product list 2015 quartett Immunodiagnostika, Biotechnologie + Kosmetik Vertriebs GmbH welcomes you as one of our new business partners as well as all of our previous loyal clients. You are now member of quartett´s worldwide customers. First of all we would like to introduce ourselves to you. Founded as a family-run company in 1986, quartett ensures for more than a quarter of a century consistent quality of products. Service and support of our valued customers are our daily businesses. And we will continue! In the end 80´s quartett offered radioimmunoassay and enzyme immunoassay kits from different manufacturers in the USA. In the beginning 90´s the company changed its strategy from offering products for routine diagnostic to the increasing field of research and development. Setting up a production plant in 1997 and a second one in 2011 supported this decision. The company specialized its product profile in the field of manufacturing synthetic peptides for antibody production, peptides such as protease inhibitors, biochemical reagents and products for histology, cytology and immunohistology. All products are exclusively manufactured in Germany without outsourcing any production step. Nowadays, we expand into all other diagnostic and research fields and supply our customers in universities, government institutes, pharmaceutical and biotechnological companies, hospitals, and private doctor offices.
    [Show full text]
  • Drug Testing Program
    DRUG TESTING PROGRAM Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING CONTENTS 1. DRUG-FREE COMPETITION 2. ATHLETE CONSENT 3. DRUG TESTING 4. IN-COMPETITION/OUT-OF-COMPETITION DRUG TESTING 5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING) 6. REMOVAL FROM TESTING POOL/RETIREMENT 6A. REMOVAL FROM TESTING POOL/WATCH LIST 7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION 8. DRUG TEST NOTIFICATION AND ADMINISTRATION 9. SPECIMEN ANALYSIS 10. REPORTING RESULTS 11. DRUG TESTING POLICY VIOLATIONS 12. ENFORCEMENT/SANCTIONS 13. APPEALS PROCESS 14. LEADERBOARD DISPLAY 15. EDUCATION 16. DIETARY SUPPLEMENTS 17. TRANSGENDER POLICY 18. THERAPEUTIC USE EXEMPTION APPENDIX A: 2020-2021 CROSSFIT BANNED SUBSTANCE CLASSES APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION) APPENDIX C: TUE APPLICATION REQUIREMENTS Drug Testing Policy V4 Copyright © 2021 CrossFit, LLC. All Rights Reserved. CrossFit is a registered trademark ® of CrossFit, LLC. [ 2 ] 2021 DRUG TESTING PROGRAM 2021 DRUG TESTING 1. DRUG-FREE COMPETITION As the world’s definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy or some over-the-counter performance-enhancing supplements, has the potential to compromise the integrity of the competition and must be disallowed. With the health, safety, and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit, LLC has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Glycerol Dehydrogenase from Gluconobacter Industrius
    Agric. Biol Chem., 49 (4), 1001 -1010, 1985 1001 Solubilization, Purification and Properties of Membrane-bound Glycerol Dehydrogenase from Gluconobacter industrius Minoru Ameyama,Emiko Shinagawa, Kazunobu Matsushita and Osao Adachi Laboratory of Applied Microbiology, Department of Agricultural Chemistry, Faculty of Agriculture, Yamaguchi University, Yamaguchi 753, Japan Received July 30, 1984 Membrane-bound glycerol dehydrogenase was solubilized and purified about 100-fold from the membraneof Gluconobacter industrius IFO 3260 grown on a glycerol-glutamate medium. Solubilization of the enzyme was successfully achieved by use of 0.5% dimethyldodecylamineoxide in 0.05 m Tris-HCl, pH 8.0. Alcohol dehydrogenase and D-glucose dehydrogenase, which were abundantly formed in the same bacterial membrane, were eliminated on solubilization. Glycerol dehydrogenase was further purified through fractionation with polyethylene glycol 6000. The enzymeshowed a broad substrate specificity and various kinds of polyhydroxyl alcohols, in addition to glycerol, were rapidly oxidized in the presence of 2,6-dichlorophenolindophenoi and phenazine methosulfate as the electron acceptor but NADand NADPwere inert. The enzyme was proved to be a quinoprotein in which pyrroloquinoline quinone functioned as the prosthetic group. The first report on microbial oxidation of localization of the oxidase system in cells of G. glycerol to dihydroxyacetone was by Bertrand liquefaciens and found that the oxidation of with a strain capable of L-sorbose fermen- glycerol and raeso-erythritol
    [Show full text]
  • Recombinant Escheichia Coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate
    J. Ind. Eng. Chem., Vol. 12, No. 5, (2006) 757-761 Recombinant Escheichia coli-Catalyzed Production of Cytidine 5′-Triphosphate from Cytidine 5′-Monophosphate Sun-Gu Lee† and Byung-Gee Kim* Department of Chemical and Biochemical Engineering, Pusan National University, Busan 609-735, Korea *School of Chemical Engineering, and Institute of Molecular Biology and Genetics, Seoul National University, Seoul 151-742, Korea Received April 24, 2006; Accepted May 22, 2006 Abstract: A recombinant Escherichia coli overexpressing CMP-kinase was constructed and employed as a whole cell biocatalyst for the conversion of cytidine 5′-monophosphate to cytidine 5′-triphosphate. In the whole cell biocatalysis, recombinant CMP kinase catalyzed the conversion of CMP to CDP, and endogenous acetate kinase of the E. coli was utilized for the ATP regeneration as well as for the conversion of CDP to CTP. A conversion yield of ca. 88 % CTP was obtained when starting with 20 mM CMP, 1 mM ATP, and 80 mM acetyl phosphate based on the initial CMP concentration. Endogenous pyruvate kinase and poly- phosphate kinase were inefficient in the process. The CTP production system was applied to the production of CMP-NeuAc by additionally introducing the CMP-NeuAc synthetase gene into the recombinant E. coli. Keywords: CMP-kinase, whole cell biocatalysis, ATP regeneration, cytidine 5′-monophosphate Introduction employing enzymes [4]. They applied various enzymatic 1) methods and chemical methods and concluded that the As glycosyltransferase-catalyzed synthetic techniques enzymatic method based on adenylate kinase/pyruvate are becoming recognized as powerful methods for the kinase provided the most convenient route to CTP. In the preparation of biologically important oligosaccharides, process, CTP was generated efficiently from an inexpen- the development of cost-efficient production methods for sive substrate, CMP.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges
    Current Diabetes Reports (2019) 19:102 https://doi.org/10.1007/s11892-019-1211-9 OBESITY (KM GADDE, SECTION EDITOR) Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges Martha A. Schalla1 & Andreas Stengel1,2 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Obesity is affecting over 600 million adults worldwide and has numerous negative effects on health. Since ghrelin positively regulates food intake and body weight, targeting its signaling to induce weight loss under conditions of obesity seems promising. Thus, the present work reviews and discusses different possibilities to alter ghrelin signaling. Recent Findings Ghrelin signaling can be altered by RNA Spiegelmers, GHSR/Fc, ghrelin-O-acyltransferase inhibitors as well as antagonists, and inverse agonists of the ghrelin receptor. PF-05190457 is the first inverse agonist of the ghrelin receptor tested in humans shown to inhibit growth hormone secretion, gastric emptying, and reduce postprandial glucose levels. Effects on body weight were not examined. Summary Although various highly promising agents targeting ghrelin signaling exist, so far, they were mostly only tested in vitro or in animal models. Further research in humans is thus needed to further assess the effects of ghrelin antagonism on body weight especially under conditions of obesity. Keywords Antagonist . Ghrelin-O-acyl transferase . GOAT . Growth hormone . Inverse agonist . Obesity Abbreviations GHRP-2 Growth hormone–releasing peptide-2 ACTH Adrenocorticotropic hormone GHRP-6 Growth hormone–releasing peptide 6 AZ-GHS-22 Non-CNS penetrant inverse agonist 22 GHSR Growth hormone secretagogue receptor AZ-GHS-38 CNS penetrant inverse agonist 38 GOAT Ghrelin-O-acyltransferase BMI Body mass index GRLN-R Ghrelin receptor CpdB Compound B icv Intracerebroventricular CpdD Compound D POMC Proopiomelanocortin DIO Diet-induced obesity sc Subcutaneous GH Growth hormone SPM RNA Spiegelmer WHO World Health Organization.
    [Show full text]
  • Découverte D'une Nouvelle Famille De Protéine Kinases Bactériennes
    Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis Hien-Anh Nguyen To cite this version: Hien-Anh Nguyen. Découverte d’une nouvelle famille de protéine kinases bactériennes : mécanismes de fonctionnement et rôle cellulaire de YdiB, un archétype chez Baccillus subtilis. Sciences agricoles. Université de Grenoble, 2012. Français. NNT : 2012GRENV017. tel-00721757 HAL Id: tel-00721757 https://tel.archives-ouvertes.fr/tel-00721757 Submitted on 30 Jul 2012 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITÉ DE GRENOBLE Spécialité : Chimie-Biologie Arrêté ministériel : 7 août 2006 Présentée par Hien-Anh NGUYEN Thèse dirigée par le Dr. Jean-Michel JAULT préparée au sein de l’Institut de Biologie Structurale J.-P. Ebel, et du CEA de Grenoble dans l'École Doctorale Chimie et Sciences du Vivant Découverte d’une nouvelle famille de protéines kinases bactériennes : Mécanisme de fonctionnement et rôle cellulaire de YdiB, un représentant chez B. subtilis Thèse soutenue publiquement le 23 mai 2012 devant le jury composé de : Mme. Patricia DOUBLET Rapporteur Prof.
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]